New drugs are needed for preventing drug-resistant Plasmodium falciparum malaria. The prophylactic efficacy of azithromycin against P. falciparum in malaria-immune Kenyans was 83%. We conducted a double-blind, placebo-controlled trial to determine the prophylactic efficacy of azithromycin against multidrug-resistant P. falciparum malaria and chloroquine-resistant Plasmodium vivax malaria in Indonesian adults with limited immunity. After radical cure therapy, 300 randomized subjects received azithromycin (148 subjects, 750-mg loading dose followed by 250 mg/d), placebo (77), or doxycycline (75, 100 mg/d). The end point was slide-proven parasitemia. There were 58 P. falciparum and 29 P. vivax prophylaxis failures over 20 weeks. Using incidence rates, the protective efficacy of azithromycin relative to placebo was 71.6% (95% confidence interval [CI], 50.3 -83.8) against P. falciparum malaria and 98.9% (95% CI, 93.1 -99.9) against P. vivax malaria. Corresponding figures for doxycycline were 96.3% (95% CI, 85.4 -99.6) and 98% (95% CI, 88.0 -99.9), respectively. Daily azithromycin offered excellent protection against P. vivax malaria but modest protection against P. falciparum malaria.
Malaria is a serious global public health problem. The World chloroquine-resistant Plasmodium vivax is now an emerging Health Organization estimates that there are 300 -500 million threat [7, 8] . cases of clinical malaria each year worldwide with 1.5 to 2. 7 Prophylactic drugs must have high efficacy and low toxicity. million deaths attributable to Plasmodium falciparum [1, 2] .
Mefloquine, doxycycline, and chloroquine/proguanil are curChemoprophylaxis for malaria is aimed at two distinct rently recommended as prophylaxis for chloroquine-resistant groups: nonimmune individuals of all ages who travel to areas P. falciparum malaria [3, 9, 10] . None of these drugs is ideal. where malaria is endemic [3] and pregnant women living in Doxycycline is contraindicated in pregnancy [3, 10] and chilareas of endemicity [4] . Antimalarial drugs for prophylaxis and dren younger than 8 years of age [9] . Mefloquine is contrainditreatment are becoming increasingly ineffective because of the cated for patients with a history of epilepsy or serious psychiatcontinuing rise of multidrug-resistant P. falciparum malaria in ric disease [9] . The World Health Organization [3] and the most areas where malaria is endemic [5, 6] . Malaria due to British authorities [10] recommend avoidance of mefloquine in the first trimester of pregnancy, but the Centers for Disease Control and Prevention support the use of mefloquine if travel to an area where chloroquine-resistant malaria occurs is unReceived 6 May 1998; revised 24 August 1998. avoidable [9] . Chloroquine and proguanil are safe in pregnancy
Informed consent was obtained from all study subjects, and the regulations [10, 11] , but this combination has low efficacy [12, 13] .
governing the protection of human subjects of the Indonesian Ministry of Health, the Indonesian Army, and the U.S. Navy and Army were followed in Azithromycin, an azalide antibiotic similar to erythromycin, the conduct of this study.
had good antimalarial activity in human malaria challenge stud-
The views expressed in this article are those of the authors and do not in any way represent those of the Indonesian Army, the Indonesian Ministry of ies [14, 15] . When azithromycin was used for treating Gambian Health, or the U.S. Army and Navy. children with trachoma, spleen rates, parasite counts, and the Financial support: This study was supported by the U.S. Army Medical number of episodes of febrile parasitemia due to P. falciparum for a population with low or no immunity were high, then nation of a blood smear for malaria; determination of complete blood count (Coulter Electronics, Hialeah, FL); biochemistry azithromycin would be a substantial addition to the present pool of prophylactic drugs.
analysis: sodium, potassium, creatinine, aspartate aminotransferase, alkaline phosphatase, and total bilirubin (Kodak, RochWe report the protective efficacy of daily azithromycin given to Indonesian adults with limited immunity to malaria who ester, NY); determination of qualitative glucose-6-phosphatedehydrogenase activity (G6PD spot test, Sigma, St. Louis); resided in an area where multidrug-resistant P. falciparum malaria and chloroquine-resistant P. vivax malaria occur.
urine dipstick (Boehringer Mannheim, Mannheim, Germany); and urine pregnancy test (b HCG test pack, Abbott Laboratories, Chicago).
Methods
Eligible subjects were healthy males or nonpregnant females aged 18 to 55 years. Exclusion criteria included clinically sigStudy Design nificant disease, hepatic disease, history of splenectomy, hearThis was a randomized, double-blind, placebo-controlled ing impairment (abnormal Rinné or Weber's test), glucose-6-study estimating the prophylactic efficacy of daily azithromycin phosphate dehydrogenase deficiency, known study drug hyperagainst P. falciparum malaria and P. vivax malaria and assensitivity, and residence for ú18 months in Arso. sessing toxicity. Doxycycline served as a positive control beEnrolled subjects were given radical cure therapy to elimicause of its high prophylactic efficacy in a randomized control nate blood and liver forms of malaria. The regimen was concurtrial in the same area in 1994 [19] . rent quinine sulfate (10 mg/kg twice daily [thrice daily if there was parasitemia] for 4 days), doxycycline (100 mg twice daily for 10 days), and primaquine base (30 mg daily for 14 days).
Study Site and Participants
In previous studies in Irian Jaya, this regimen was used successThe study took place between July 1996 and January 1997 fully to clear patent parasitemia and to prevent recurrent parain Arso (a rural part of northeast Irian Jaya, close to Jayapura) sitemia for at least 2 weeks after treatment (T. Richie, unpubwhere multidrug-resistant P. falciparum malaria [20] [21] [22] [23] and lished observations). chloroquine-resistant P. vivax malaria [8, 24] After subjects had completed radical cure therapy, they were between 0.54 and 11.7 infective bites per person per month [25] .
sequentially assigned a study number and the corresponding We recruited Indonesian Army soldiers from posts that were study drug code from a computer-generated randomization list. located near villages and housed Ç12 men. They had arrived Blocked randomization with an average block size of four 6 months earlier from southern Sumatra and were taking doxy-(computer-generated with a variable block size) was used to cycline, chloroquine, or sulfadoxine pyrimethamine as malaria assign the three study drugs azithromycin, placebo, and doxyprophylaxis (the latter two drugs were changed to doxycycline cycline to achieve an expected 2:1:1 ratio after every four after the arrival of our team). Civilians were immigrant farmers subjects were randomized. The statistical framework [26] for from Java who were residents in one village (Arso PIR V) for determining the sample size was based on the objective of 15 months. They had received free chloroquine prophylaxis estimating the protective efficacy of azithromycin to rule out during the first 3 months after their arrival from the government a level of õ70%. To reduce the number of subjects assigned clinic, which also provided free basic health care. Villagers to placebo and to increase power, we used an allocation of two could also buy antimalarial drugs in local shops. Soldiers and azithromycin recipients to one placebo recipient. Assuming an civilians used bed nets that were not insecticide-impregnated. attack rate of 60% over 20 weeks and an anticipated reduction The incidence of malaria is low in Java and the area of southern in the number of prophylaxis failures of 85% with azithroSumatra where the soldiers were based (F. Laihad, unpublished mycin, a total of 195 subjects (130 azithromycin recipients and data).
65 placebo recipients) would be required to have 80% power We obtained written informed consent from all study volunto rule out a protective efficacy of õ70% (5% type I error; teers. The study was conducted according to the regulations of one-sided). The number of subjects receiving doxycycline was the Indonesian Ministry of Health, the Indonesian Army, and the same as the number of placebo recipients. To allow for the U.S. Navy and Army that govern the protection of human dropouts, the final target number of volunteers to be randomsubjects.
ized was 300.
Prestudy Assessment and Radical Cure Treatment Blinding and Drug Packaging
No field-based investigator knew the randomization code. It The screening of potential subjects consisted of the following: obtaining a medical history; physical examination; examiwas securely stored in individually sealed envelopes and was / 9c5e$$ja06 12-28-98 16:19:37 cida UC: CID broken only if a subject had a serious adverse event necessitatwithdrawals or protocol violations), follow-up time was measured to the date of the last negative slide. Nonmalaria reasons ing study withdrawal.
Study drugs and identical placebo (azithromycin and plafor withdrawal from the study were as follows: serious adverse event, unsupervised drug administration for ú14 days, concebo, red tablets; doxycycline and placebo, white capsules) were supplied in blister packs (Pfizer Central Research, Groton sumption of a nonstudy antimalarial drug, two doses of study drug or placebo missed within 7 days, and voluntary dropout. CT). Labeled drug packs containing a 1-week supply of both azithromycin or placebo and doxycycline or placebo were made; two extras of each drug were included in case of emesis Assessment of Study Drug Tolerance within 1 hour of drug administration.
Tolerance was assessed by interviewing subjects with a 26-symptom questionnaire on day 0 and day 1 (tolerance to
Conduct of Clinical Trial
loading dose) and by recording symptoms every day in answer Radical cure therapy was initiated over a 7-week period.
to the open question ''Any symptoms?''. Blood samples were Administration of study drugs commenced the day after radical obtained for determination of complete blood counts and biocure (day 0). All doses were given using the double-dummy chemistry at enrollment, 1 month into the study, and at study method -the simultaneous administration of an active drug end. All safety and tolerance data for volunteers who were and placebo. On day 0, all subjects received one doxycycline removed from follow-up for efficacy (those with protocol viola-(100 mg) or placebo capsule and a loading dose (three tablets) tions) but who continued to receive study drug or placebo were of azithromycin (750 mg) or placebo; based on a computerincluded in the analyses of drug safety and tolerance. simulated model, the loading dose ensured the attainment of 90% of steady-state serum and tissue levels by day 1. Thereafter, one azithromycin (250 mg) or placebo tablet and one doxyStatistical Analysis cycline (100 mg) or placebo capsule were given daily over a follow-up period of 20 weeks. Drinking water and sweet bisData for all 300 randomized volunteers were included in the analyses of efficacy and drug safety and tolerance. Data were cuits were provided with each dose.
Drug administration and consumption were witnessed and entered twice, discrepancies resolved, and end points finalized before the databases were locked and the randomization code signed for by a health worker and the subject. If a soldier was absent, his post commander was given study drugs, sweet was broken. Epi Info Version 6.02 (Centers for Disease Control and Prevention), Minitab 11 for Windows (Minitab, State Colbiscuits, and a record book. The post commander was responsible for administering and recording drug administration. Sollege, PA), and Statxact 3 for Windows (CYTEL Software, Cambridge, MA) were used for data management and analysis. diers away on patrol were given a 2-week supply of study drugs. Drug forms were inspected daily, supplemented by periEfficacy. IRs (density) were calculated as the number of malaria cases divided by the total person-years of follow-up. odic drug counts and supervisory field visits.
Thick and thin blood smears were made weekly, or sooner The protective efficacy (PE) was defined as the percent reduction (drug relative to placebo) in the IRs of malaria and was if clinically indicated. Giemsa-stained slides were read by microscopists who were unaware of the symptom status of the calculated as 1 0 drug IR: placebo IR. Confidence intervals for the PE (1 0 ratio of two Poisson variables) were calculated subject. A positive slide was defined as two or more asexual malarial parasites seen after reading 200 thick smear fields at by using the exact conditional distribution [28] . Koopman's method was used to obtain confidence intervals for the PE (or 11,000 magnification. All positive slides were confirmed by a second microscopist in a blinded fashion. Parasitemia was other effect measures) based on the ratio of two proportions [29] . quantified as the number of thick smear asexual parasites per 200 WBCs 1 40 [27].
The Kaplan-Meier method was used to estimate the cumulative risk ({SE) of developing either falciparum or vivax maAll subjects with parasitemia were interviewed by a study doctor. One or more of the following defined symptomatic laria during follow-up; the follow-up time was considered censored if one malaria species occurred before the other. parasitemia: fever, chills, sweating, myalgia, headache, anorexia, nausea, vomiting, abdominal pain, and/or diarrhea.
Cumulative risk curves were compared by the logrank test [30] . Student's unpaired and paired t-tests were used to assess differences between and within groups, respectively, in mean
End Points values for continuous laboratory data. Differences in proportions were compared by using the x 2 or Fisher's exact test. The primary efficacy end point was the first occurrence of slide-proven parasitemia (prophylaxis failure). Follow-up time
The Mann-Whitney U test was used to compare median parasite counts or other highly skewed data [31] . All reported confifor efficacy analysis was defined as the time from day 0 to the date of prophylaxis failure or the date of study completion. For dence intervals are 95%, and all reported P values are twosided. those subjects not completing scheduled follow-up (i.e., study / 9c5e$$ja06 12-28-98 16:19:37 cida UC: CID All reported malaria within 1 year of study enrollment was based on history and had occurred since the subject's arrival NOTE. AST Å aspartate aminotransferase.
in Irian Jaya. Certain markers of recent malaria exposure were * Reported number of malaria illnesses per subject (not microscopically confirmed) within 1 year of study enrollment. significantly higher in the civilians than in the soldiers (see below under Subgroup Analysis of Civilians and Soldiers).
One hundred fifty-four subjects (51.3%) completed the study as per protocol without acquiring parasitemia. Eighty-seven subjects (29%) developed parasitemia, and 59 (19.7%) withdrew from the study for other reasons (figure 1). The median follow-up time for all subjects in each arm was as follows: doxycycline, 16.1 weeks (range, 2.4 -20.1 weeks); azithromycin, 15.8 weeks (range, 1.1 -20.1 weeks); and placebo, 7.6 weeks (range, 0 -18.6 weeks). The differences in these followup times were due to the different rates of parasitemia acquisition (figure 2).
Parasitemia End Points
There were 87 cases of parasitemia (table 2): 55 P. falciparum, 29 P. vivax, and 3 cases of mixed infection that were counted as P. falciparum, the dominant species in each case. The number (%) of cases of parasitemia per the total number of randomized subjects in each treatment arm was as follows: placebo, 56 (72.7%) of 77; azithromycin, 28 (18.9%) of 148; and doxycycline, 3 (4%) of 75.
Most subjects (66 [75.9%] of 87) had symptomatic parasitemia. By species, these symptomatic infections were due to Of the 26,857 intended doses, 25,181 (93.8%) were administered under direct observation by our team, 860 (3.2%) were witnessed by a post commander, 781 (2.9%) were taken unwitnessed, and 35 (0.1%) were not taken.
Overall, the study drugs were well tolerated (further details will be reported elsewhere). One azithromycin recipient who developed an erythematous, maculopapular rash was withdrawn from the study. There were seven other serious adverse events that were all considered unrelated to the study drugs: azithromycin group -ureteric stone, possible dengue fever, and motor cycle accident; doxycycline group -acute bronchitis with hyperventilation and subarachnoid hemorrhage; and placebo group -headache with photophobia and severe malaria. Three of these subjects were withdrawn from the study. The loading dose was well tolerated by the azithromycin Plasmodium falciparum (Pf) or Plasmodium vivax (Pv) malaria in subjects receiving placebo (n Å 77), azithromycin (n Å 148), or group; there were no significant differences in the proportions doxycycline (n Å 75).
of subjects with a new symptom on day 1 between all three drug groups. The daily symptoms in the azithromycin and placebo groups were compared; azithromycin recipients reported a higher frequency of heartburn, paresthesia, and itching, 1 P. vivax; 71.4%) of 28 azithromycin recipients, and 1 (1 P.
whereas placebo recipients complained more often of fever, falciparum; 33.3%) of 3 doxycycline recipients. Symptomatic diarrhea, severe headache, tinnitus, and blurred vision. No resubjects had a mean of 3.8 symptoms, and 55 (83.3%) of 66 ported symptom exceeded 3.6 complaints per person-year. Hesubjects had more than one symptom. The three most common matologic and biochemistry values did not significantly differ symptoms were headache (51 [77.3%]), myalgia (41 [62.1%]), over time within or between study groups. and fever (33 [50%] ).
The median level of P. falciparum parasites in placebo recipients was 1,480/mL (range, 60-32,920/mL) compared with 280/mL
Subgroup Analysis of Civilians and Soldiers
(range, 80-700/mL) in azithromycin recipients (P Å .023).
We compared certain civilian data with soldier data (table  3) . At enrollment, the four malariometric indices showed that, since their arrival in Irian Jaya, the civilians had significantly Prophylactic Efficacy more prestudy malaria exposure than the soldiers. However, the outcomes for civilians and soldiers who received placebo Compared to placebo, the prophylactic efficacy of azithromycin was 71.6% (95% CI, 50.3 -83.8) against P. falciparum were not significantly different with respect to overall attack rate, occurrence of symptomatic parasitemia, and levels of parmalaria and 98.9% (95% CI, 93.1 -99.9) against P. vivax malaria (table 2) . Corresponding figures for doxycycline were asitemia (P. falciparum or P. vivax). Although the estimated protective efficacy of azithromycin against P. falciparum was 96.3% (95% CI, 85.4 -99.6) and 98% (95% CI, 88.0 -99.9), respectively.
higher for the civilians (88.4% [95% CI, 56.6 -97.4]) compared [13] ). The difvide the best evidence for drug efficacy and tolerance [10] . We ference between soldiers and civilians was not statistically sigfollowed a large number of subjects with 6 -15 months of nificant, but we believe that the prophylactic efficacy for the malaria exposure who lived under basic field conditions, akin soldiers approximates that of a malaria-naive population. to those experienced by backpackers, missionaries, refugees, Therefore, for nonimmune populations (a major group receivand deployed soldiers. They suffered moderately intense maing prophylaxis), 250 mg of azithromycin daily cannot be reclaria transmission, confirmed by the crude attack rate of just ommended as a first-line drug against P. falciparum, the species under 73% among the placebo group during the course of the causing severe malaria and high mortality [2] . study. The high prophylactic efficacy of the doxycycline posiComparable data evaluating azithromycin for malaria prophytive control excludes poor drug compliance as a cause of the laxis are limited. In Kenyan adults, daily azithromycin (250 mg; low falciparum result. no loading dose) had a prophylactic efficacy (based on crude To recommend a drug for malaria prophylaxis, that drug incidence) of 83% (95% CI, 68-91) against falciparum malaria must have low toxicity and offer good protection comparable [17] ; the entomological inoculation rate in Kenya (30 infective with that of the current first-line drugs. There is no generally bites per month) is higher than that in Irian Jaya, and the subjects accepted minimum efficacy. This trial adopted a priori a minimum acceptable protective efficacy of 70% (lower 95% CI, of the Kenyan study were lifelong residents. None of the subjects cating a high degree of clinical immunity [17, 32] . In contrast, our soldiers and civilians had less clinical immunity because most were symptomatic. However, the similarity of the efficacy results between our civilians and the Kenyans
